$PFE News Pfizer and Kaiser: They not only rhyme, they're

New Post Public Reply Private Reply Replies (0) Message Board

Dec 20, 2013 at 12:30 PM

$PFE News

Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - blogs.marketwatch.com
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Value investing for retirement portfolios 6:01 a.m. Dec. 7, 2013 - Robert Powell
Auxilium shares soar after FDA approves drug for additional use 3:53 p.m. Dec. 6, 2013 - blogs.marketwatch.com
A tale of two drug companies 4:13 p.m. Dec. 5, 2013 - Mark Hulbert
3 low-risk stocks for market skeptics 6:15 a.m. Dec. 5, 2013 - Jeff Reeves
DuPont, Pfizer are top decliners in Dow index 4:01 p.m. Dec. 3, 2013 - Polya Lesova
Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Pfizer's Rapamune doesn't meet primary endpoint 8:51 a.m. Nov. 8, 2013 - MarketWatch.com
Is this March 2000 all over again? 3:07 p.m. Nov. 7, 2013 - Mark Hulbert
Newscast: The Dow and S&P 500 set new record highs 6:31 p.m. Oct. 29, 2013 - MarketWatch
Energy stocks gain; BP shares rally on earnings 5:12 p.m. Oct. 29, 2013 - Claudia Assis
S&P 500, Dow industrials close at record highs 4:41 p.m. Oct. 29, 2013 - Victor Reklaitis
Newscast: Wall Street heads higher and sets record 4:33 p.m. Oct. 29, 2013 - MarketWatch
U.S. stocks open higher; Pfizer rises 1% 9:36 a.m. Oct. 29, 2013 - Victor Reklaitis
Stock futures up slightly ahead of Fed meeting 9:04 a.m. Oct. 29, 2013 - Sara Sjolin

Pfizer Inc's Buy Recommendation Affirmed 9:00 a.m. Today - TheStreet.com
IPO Market Wraps Up Big Year 11:23 p.m. Dec. 19, 2013 - WSJ.com
'Dogs of the Dow' Strategy Should Be Muzzled 6:42 p.m. Dec. 19, 2013 - Barrons.com
Bristol-Myers' Diabetes Sale Sharpens Biopharma Focus 5:37 p.m. Dec. 19, 2013 - Investors Business Daily
Pfizer’s Viagra Going Generic: Cheaper Options Coming Soon 5:26 p.m. Dec. 19, 2013 - Wall St. Cheat Sheet
Astra Buys Stake in Diabetes Venture 4:10 p.m. Dec. 19, 2013 - WSJ.com
5 Core Conservative Growth Stocks For A Retiree's Portfolio 3:36 p.m. Dec. 19, 2013 - Seeking Alpha
BlackBerry Future May Be Clearer With Earnings Report 1:10 p.m. Dec. 19, 2013 - Investors Business Daily
Stock Market News for December 19, 2013 - Market News 10:06 a.m. Dec. 19, 2013 - Zacks.com
Dow Today: Pfizer (PFE) Leads The Day Higher, UnitedHealth Group (UNH) Lags 10:00 a.m. Dec. 19, 2013 - TheStreet.com
Sanofi Pipeline Doesn't Support Price 6:00 a.m. Dec. 19, 2013 - TheStreet.com
Pfizer Inc (PFE): Today's Featured Drugs Winner 5:00 p.m. Dec. 18, 2013 - TheStreet.com
Top Five Guru-Held Health Care Stocks 4:42 p.m. Dec. 18, 2013 - GuruFocus.com
Elite Pharmaceuticals: Swinging For The Fences 10:53 a.m. Dec. 18, 2013 - Seeking Alpha
Novartis Answers Critics 6:30 a.m. Dec. 18, 2013 - TheStreet.com
Teva Secures Rights to Launch Generic Viagra 6:04 a.m. Dec. 18, 2013 - 247WallSt.com
Corporate Watch 11:28 p.m. Dec. 17, 2013 - WSJ.com
Recent Moves By Pfizer Management: No Big Deal Or Telegraphing A Sell-Off? 5:28 p.m. Dec. 17, 2013 - Seeking Alpha
Pfizer's Schulman to Leave Company 3:08 p.m. Dec. 17, 2013 - WSJ.com
Amgen's evolocumab looks comparable to competition in fight against LDL-C 2:46 p.m. Dec. 17, 2013 - Seeking Alpha

Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Today - ACCESSWIRE
Patent Settlements, Stock Price Movements, and Financial Guidance - Research Report on Pfizer, Tenet, Rockwell Medical, Magellan Health Services, and HealthSouth 8:00 a.m. Today - PR Newswire
FDA Accepts For Review ELIQUIS(R) (apixaban) Supplemental New Drug Application for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE 5:01 p.m. Dec. 19, 2013 - BusinessWire
Athersys Confirms Completion of Patient Enrollment of Pfizer's Phase II Study of MultiStem(R) Cell Therapy for Ulcerative Colitis 7:00 a.m. Dec. 19, 2013 - GlobeNewswire
Surgical Scar Market Is Ripe for Innovation 11:15 a.m. Dec. 18, 2013 - ACCESSWIRE
Healthcare Companies Report Interim Data, Clinical Study Results, and Announcements - Research Report on Pfizer, Coronado Biosciences, Spectranetics, Celsion, and Intercept 8:00 a.m. Dec. 18, 2013 - PR Newswire
Teva Settles Viagra(R) Patent Litigation with Pfizer 4:35 p.m. Dec. 17, 2013 - BusinessWire
Pfizer Settles Viagra(R) Patent Litigation With Teva 11:55 a.m. Dec. 17, 2013 - BusinessWire
Pfizer Invites Public To View And Listen To Webcast Of January 28 Conference Call With Analysts 10:00 a.m. Dec. 17, 2013 - BusinessWire
Pfizer Names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business 9:00 a.m. Dec. 17, 2013 - BusinessWire
Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development 8:01 a.m. Dec. 17, 2013 - Marketwire
Pfizer Declares First-Quarter 2014 Dividend 11:20 a.m. Dec. 16, 2013 - BusinessWire
InvestorsObserver releases comments on Pfizer, Oracle, FedEx, Jabil Circuit, and Trulia 9:31 a.m. Dec. 16, 2013 - PR Newswire
Siemens Enters Into Master Agreement With Pfizer for Companion Diagnostics 9:26 a.m. Dec. 16, 2013 - BusinessWire
Critical Alerts For Pfizer, Halliburton, Joy Global, Anadarko Petroleum, and Hewlett Packard Released By InvestorsObserver 9:31 a.m. Dec. 12, 2013 - PR Newswire
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant 8:59 a.m. Dec. 11, 2013 - BusinessWire
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant 6:00 a.m. Dec. 11, 2013 - BusinessWire
Pharma Industry Morning Assessment: Pfizer, Merck & Co., AbbVie, and Zogenix 12:19 p.m. Dec. 10, 2013 - PR Newswire
New Clinical Data Access Policy, Portfolio Expansions, Positive Top Line Results and Stock Price Movements - Research Report on Pfizer, Amgen, Puma Biotechnology, Abbott Laboratories, and Agilent 8:00 a.m. Dec. 10, 2013 - PR Newswire
Jason Hahn Named Chief Client Officer at WestLake Financial Group, Inc. 5:04 a.m. Dec. 10, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....